Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

68Ga-PSMA PET/CT-based metastasis-directed radiotherapy for oligometastatic prostate cancer recurrence after radical prostatectomy.

Artigas C, Flamen P, Charlier F, Levillain H, Wimana Z, Diamand R, Albisinni S, Gil T, Velthoven RV, Peltier A, Gestel DV, Roumeguere T, Otte FX.

World J Urol. 2019 Mar 1. doi: 10.1007/s00345-019-02701-1. [Epub ahead of print]

PMID:
30824985
2.

Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68Ga-PSMA-positron emission tomography/computerized tomography.

Hijazi S, Meller B, Leitsmann C, Strauss A, Meller J, Ritter CO, Lotz J, Schildhaus HU, Trojan L, Sahlmann CO.

Prostate. 2015 Dec;75(16):1934-40. doi: 10.1002/pros.23091. Epub 2015 Sep 10.

PMID:
26356236
3.

Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.

Baumann R, Koncz M, Luetzen U, Krause F, Dunst J.

Strahlenther Onkol. 2018 Apr;194(4):318-324. doi: 10.1007/s00066-017-1239-1. Epub 2017 Nov 27.

4.

Initial multicentre experience of 68 gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited.

Siriwardana A, Thompson J, van Leeuwen PJ, Doig S, Kalsbeek A, Emmett L, Delprado W, Wong D, Samaratunga H, Haynes AM, Coughlin G, Stricker P.

BJU Int. 2017 Nov;120(5):673-681. doi: 10.1111/bju.13919. Epub 2017 Jun 20.

5.

Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].

Calais J, Czernin J, Fendler WP, Elashoff D, Nickols NG.

BMC Cancer. 2019 Jan 7;19(1):18. doi: 10.1186/s12885-018-5200-1. Erratum in: BMC Cancer. 2019 Jan 21;19(1):97.

6.

Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.

Schmidt-Hegemann NS, Fendler WP, Buchner A, Stief C, Rogowski P, Niyazi M, Eze C, Li M, Bartenstein P, Belka C, Ganswindt U.

Radiat Oncol. 2017 Nov 10;12(1):176. doi: 10.1186/s13014-017-0902-0.

7.

Detection Efficacy of Hybrid 68Ga-PSMA Ligand PET/CT in Prostate Cancer Patients with Biochemical Recurrence After Primary Radiation Therapy Defined by Phoenix Criteria.

Einspieler I, Rauscher I, Düwel C, Krönke M, Rischpler C, Habl G, Dewes S, Ott A, Wester HJ, Schwaiger M, Maurer T, Eiber M.

J Nucl Med. 2017 Jul;58(7):1081-1087. doi: 10.2967/jnumed.116.184457. Epub 2017 Feb 16.

8.

68Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients.

Caroli P, Sandler I, Matteucci F, De Giorgi U, Uccelli L, Celli M, Foca F, Barone D, Romeo A, Sarnelli A, Paganelli G.

Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2035-2044. doi: 10.1007/s00259-018-4067-3. Epub 2018 Jun 19.

PMID:
29922948
9.

(11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series.

Graziani T, Ceci F, Castellucci P, Polverari G, Lima GM, Lodi F, Morganti AG, Ardizzoni A, Schiavina R, Fanti S.

Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):1971-9. doi: 10.1007/s00259-016-3428-z. Epub 2016 Jun 8.

PMID:
27277279
10.

Patterns of Progression After 68Ga-PSMA-Ligand PET/CT-Guided Radiation Therapy for Recurrent Prostate Cancer.

Soldatov A, von Klot CAJ, Walacides D, Derlin T, Bengel FM, Ross TL, Wester HJ, Derlin K, Kuczyk MA, Christiansen H, Henkenberens C.

Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):95-104. doi: 10.1016/j.ijrobp.2018.08.066. Epub 2018 Sep 7.

PMID:
30201438
11.

See the unseen: Mesorectal lymph node metastases in prostate cancer.

Hijazi S, Meller B, Leitsmann C, Strauss A, Ritter C, Lotz J, Meller J, Trojan L, Sahlmann CO.

Prostate. 2016 Jun;76(8):776-80. doi: 10.1002/pros.23168. Epub 2016 Feb 16.

PMID:
26880517
12.

68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy - diagnostic performance and impact on therapeutic decision-making.

Grubmüller B, Baltzer P, D'Andrea D, Korn S, Haug AR, Hacker M, Grubmüller KH, Goldner GM, Wadsak W, Pfaff S, Babich J, Seitz C, Fajkovic H, Susani M, Mazal P, Kramer G, Shariat SF, Hartenbach M.

Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):235-242. doi: 10.1007/s00259-017-3858-2. Epub 2017 Oct 26.

13.

Clinicopathological predictors of positive 68Ga-PSMA-11 PET/CT in PSA-only recurrence of localized prostate cancer following definitive therapy.

Aydin AM, Haberal B, Artykov M, Bilen CY, Yazici S.

Ann Nucl Med. 2019 May;33(5):326-332. doi: 10.1007/s12149-019-01340-1. Epub 2019 Feb 18.

PMID:
30778860
14.

(68)Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer : Early efficacy after primary therapy.

Henkenberens C, von Klot CA, Ross TL, Bengel FM, Wester HJ, Merseburger AS, Vogel-Claussen J, Christiansen H, Derlin T.

Strahlenther Onkol. 2016 Jul;192(7):431-9. doi: 10.1007/s00066-016-0982-z. Epub 2016 Jun 7.

PMID:
27272755
15.

Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy.

Schmidt-Hegemann NS, Fendler WP, Ilhan H, Herlemann A, Buchner A, Stief C, Eze C, Rogowski P, Li M, Bartenstein P, Ganswindt U, Belka C.

Radiat Oncol. 2018 Mar 2;13(1):37. doi: 10.1186/s13014-018-0983-4.

16.

Impact of 68Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy.

Bluemel C, Linke F, Herrmann K, Simunovic I, Eiber M, Kestler C, Buck AK, Schirbel A, Bley TA, Wester HJ, Vergho D, Becker A.

EJNMMI Res. 2016 Dec;6(1):78. Epub 2016 Oct 26.

17.

Detection Efficacy of 18F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy.

Giesel FL, Knorr K, Spohn F, Will L, Maurer T, Flechsig P, Neels O, Schiller K, Amaral H, Weber WA, Haberkorn U, Schwaiger M, Kratochwil C, Choyke P, Kramer V, Kopka K, Eiber M.

J Nucl Med. 2019 Mar;60(3):362-368. doi: 10.2967/jnumed.118.212233. Epub 2018 Jul 24.

18.

Could 68-Ga PSMA PET/CT become a new tool in the decision-making strategy of prostate cancer patients with biochemical recurrence of PSA after radical prostatectomy? A preliminary, monocentric series.

De Bari B, Mazzola R, Aiello D, Fersino S, Gregucci F, Alongi P, Nicodemo M, Cavalleri S, Salgarello M, Alongi F.

Radiol Med. 2018 Sep;123(9):719-725. doi: 10.1007/s11547-018-0890-7. Epub 2018 Apr 23.

PMID:
29687208
19.

The feasibility of prostate-specific membrane antigen positron emission tomography(PSMA PET/CT)-guided radiotherapy in oligometastatic prostate cancer patients.

Guler OC, Engels B, Onal C, Everaert H, Van den Begin R, Gevaert T, de Ridder M.

Clin Transl Oncol. 2018 Apr;20(4):484-490. doi: 10.1007/s12094-017-1736-9. Epub 2017 Aug 9.

PMID:
28795303
20.

A multicentre prospective clinical trial of 68Gallium PSMA HBED-CC PET-CT restaging in biochemically relapsed prostate carcinoma: Oligometastatic rate and distribution, compared to standard imaging.

McCarthy M, Francis R, Tang C, Watts J, Campbell A.

Int J Radiat Oncol Biol Phys. 2019 Mar 16. pii: S0360-3016(19)30370-0. doi: 10.1016/j.ijrobp.2019.03.014. [Epub ahead of print]

PMID:
30890448

Supplemental Content

Support Center